New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.

[1]  R. Cody,et al.  Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. , 1985, Journal of the American College of Cardiology.

[2]  D. Mancini,et al.  Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure. , 1985, Circulation.

[3]  H. White,et al.  Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure. , 1985, The American journal of cardiology.

[4]  S. Rubin,et al.  MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure. , 1985, Journal of the American College of Cardiology.

[5]  P. Reddy,et al.  MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. , 1985, Journal of the American College of Cardiology.

[6]  D. Baim,et al.  Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. , 1985, Circulation.

[7]  F. Shellock,et al.  Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure. , 1985, American heart journal.

[8]  B. Massie,et al.  Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. , 1985, Circulation.

[9]  J. Franciosa.  Intravenous amrinone: an advance or a wrong step? , 1985, Annals of internal medicine.

[10]  R. Cody,et al.  Acute dose range study of milrinone in congestive heart failure. , 1985, The American journal of cardiology.

[11]  E. Braunwald,et al.  Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. , 1985, The Journal of clinical investigation.

[12]  W. Parmley,et al.  Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure. , 1985, Journal of the American College of Cardiology.

[13]  F. Shellock,et al.  Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement. , 1985, Circulation.

[14]  M. Winniford,et al.  Assessment of the inotropic and vasodilator effects of amrinone versus isoproterenol. , 1984, The American journal of cardiology.

[15]  D. Baim,et al.  Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. , 1984, Circulation.

[16]  M. Packer,et al.  Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. , 1984, Circulation.

[17]  W. Laskey,et al.  Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure. , 1984, Journal of the American College of Cardiology.

[18]  W. Parmley,et al.  Mechanisms of improved left ventricular function following intravenous MDL 17,043 in patients with severe chronic heart failure. , 1984, American heart journal.

[19]  W. Parmley,et al.  Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients. , 1984, Journal of the American College of Cardiology.

[20]  M. Packer,et al.  Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. , 1984, American Journal of Cardiology.

[21]  F. Shellock,et al.  Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure. , 1984, American heart journal.

[22]  C. Leier,et al.  Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. , 1984, Journal of the American College of Cardiology.

[23]  G. Naccarelli,et al.  Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. , 1984, American Journal of Cardiology.

[24]  J. F. Lang,et al.  Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure. , 1984, The American journal of cardiology.

[25]  J. Cohn,et al.  Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure. , 1984, Journal of the American College of Cardiology.

[26]  M. Webb-Peploe,et al.  Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. , 1984, British heart journal.

[27]  E. Sonnenblick,et al.  Should the failing heart be stimulated? , 1984, The New England journal of medicine.

[28]  J. Franciosa.  Exercise testing in chronic congestive heart failure. , 1984, The American journal of cardiology.

[29]  M. Gerold,et al.  Cardiovascular Profile of Ro 13–6438, a Novel Positive Inotropic Agent with Vasodilating Properties , 1984, Journal of cardiovascular pharmacology.

[30]  R. Muggli,et al.  Studies on the Mechanism of Positive Inotropic Activity of Ro 13–6438, a Structurally Novel Cardiotonic Agent with Vasodilating Properties , 1984, Journal of cardiovascular pharmacology.

[31]  J. Ansell,et al.  Amrinone-induced thrombocytopenia. , 1984, Archives of internal medicine.

[32]  M. Sutton,et al.  Amrinone in the treatment of chronic cardiac failure. , 1984, Journal of the American College of Cardiology.

[33]  C. Antzelevitch,et al.  The effects of milrinone on conduction, reflection, and automaticity in canine Purkinje fibers. , 1984, Circulation.

[34]  M. Crawford,et al.  Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance. , 1984, The American journal of cardiology.

[35]  S. Rendig,et al.  Positive Inotropic Action of Amrinone: Effect of Elevated External Ca2+ , 1984, Journal of cardiovascular pharmacology.

[36]  C. Sweet,et al.  Responses to Amrinone in Isolated Cardiac Muscles from Cat, Rabbit, and Guinea Pig , 1984, Journal of cardiovascular pharmacology.

[37]  M. Webb-Peploe,et al.  The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure. , 1984, British journal of clinical pharmacology.

[38]  M. Miyazaki,et al.  Responses of isolated dog arteries to amrinone. , 1984, Cardiovascular research.

[39]  R. C. Dage,et al.  Studies on the Mechanism of the Cardiotonic Activity of MDL 19205: Effects on Several Biochemical Systems , 1984, Journal of cardiovascular pharmacology.

[40]  H. Cheng,et al.  In Vitro and In Vivo Assessment of the Cardiovascular Effects of the Cardiotonic Drug MDL 19205 , 1984, Journal of cardiovascular pharmacology.

[41]  C. P. Hsieh,et al.  Cardiovascular Properties of a New Cardiotonic Agent, MDL 19205 , 1984, Journal of cardiovascular pharmacology.

[42]  Piwonka Rw,et al.  Electrophysiological actions of amrinone in dogs with cardiac lesions. , 1983 .

[43]  Piwonka Rw,et al.  In vitro electrophysiologic properties of amrinone in mammalian cardiac tissue. , 1983 .

[44]  E. Sonnenblick,et al.  Acute inotropic stimulation with dopamine in severe congestive heart failure: beneficial hemodynamic effect at rest but not during maximal exercise. , 1983, The American journal of cardiology.

[45]  I. Kodama,et al.  Electrical and Mechanical Effects of Amrinone on Isolated Guinea Pig Ventricular Muscle , 1983, Journal of cardiovascular pharmacology.

[46]  R. Arbogast,et al.  Hemodynamic Effects of MDL 17,043, a New Cardiotonic Agent, in Patients with Congestive Heart Failure: Comparison with Sodium Nitroprusside , 1983, Journal of cardiovascular pharmacology.

[47]  E. Sonnenblick,et al.  Improvement in exercise capacity despite cardiac deteriora tion: nonivasive assessment of long-term therapy with amrinone in severe heart failure. , 1983, American heart journal.

[48]  R. Bernard,et al.  Hemodynamic and clinical response to three-day infusion of sulmazol (AR-L 115 BS) in severe congestive heart failure. , 1983, Chest.

[49]  E. Braunwald,et al.  Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure. , 1983, The New England journal of medicine.

[50]  R. Ferrari,et al.  Cardiotonic Activity of Milrinone, a New and Potent Cardiac Bipyridine, on the Normal and Failing Heart of Experimental Animals , 1983, Journal of cardiovascular pharmacology.

[51]  G. Stankus,et al.  Characterization of the Cardiotonic Effects of Milrinone, a New and Potent Cardiac Bipyridine, on Isolated Tissues from Several Animal Species , 1983, Journal of cardiovascular pharmacology.

[52]  G. Maréchal,et al.  Effects of Dobutamine and Sulmazol (AR‐L115 BS) on Myocardial Metabolism and Coronary, Femoral, and Renal Blood Flows: A Comparative Study in Normal Dogs and in Dogs with Chronic Volume Overload , 1983, Journal of cardiovascular pharmacology.

[53]  R. Magorien,et al.  Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.

[54]  E. Sonnenblick,et al.  Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. , 1983, Journal of the American College of Cardiology.

[55]  M. Wilén,et al.  Adverse effects of long-term amrinone administration in congestive heart failure. , 1983, American heart journal.

[56]  M. Webb-Peploe,et al.  Side effects of amrinone therapy. , 1983, British heart journal.

[57]  E. Sonnenblick,et al.  Sustained Hemodynamic and Clinical Effects of a New Cardiotonic Agent, WIN 47203, in Patients with Severe Congestive Heart Failure , 1983, Circulation.

[58]  B. Massie,et al.  Controlled Trial of Captopril in Chronic Heart Failure: A Rest and Exercise Hemodynamic Study , 1983, Circulation.

[59]  P. Reddy,et al.  The Acute Hemodynamic Effects of a New Agent, MDL 17,043, in the Treatment of Congestive Heart Failure , 1983, Circulation.

[60]  R. Myerburg,et al.  Amrinone Relaxes Potassium‐Induced Contracture of Failing Right Ventricular Muscle of Cats , 1983, Journal of cardiovascular pharmacology.

[61]  E. R. Garrett,et al.  Nonlinear pharmacokinetics of the new positive inotropic agent sulmazole in the dog. , 1983, Journal of pharmaceutical sciences.

[62]  D. Coltart,et al.  Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. , 1983, British heart journal.

[63]  E. Sonnenblick,et al.  Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure. , 1983, The American journal of cardiology.

[64]  N. Kondo,et al.  A Protective Effect of Coenzyme Q10 on Isolated Rabbit Ventricular Muscle Under Hypoxic Condition , 1982, Journal of cardiovascular pharmacology.

[65]  N. Taira,et al.  The improvement of cardiac performance by amrinone, a new cardiotonic drug, in an experimental failing heart preparation of the dog. , 1982, Japanese heart journal.

[66]  H. Adams,et al.  Amrinone Activates K+‐Depolarized Atrial and Ventricular Myocardium of Guinea Pigs , 1982, Circulation research.

[67]  L. Lesko,et al.  Acute Pharmacodynamics and Pharmacokinetics of Oral Amrinone , 1982, Journal of clinical pharmacology.

[68]  B. Carlin,et al.  Clinical Experience with Amrinone in Patients with Advanced Congestive Heart Failure , 1982, Journal of clinical pharmacology.

[69]  H. Cheng,et al.  Characterization of the Cardiovascular Activities of a New Cardiotonic Agent, MDL 17043 (1,3‐Dihydro-4‐methyl-5-[4-(methylthio)-benzoyl]-2H‐imidazol-2‐one) , 1982, Journal of cardiovascular pharmacology.

[70]  N. Taira,et al.  Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. , 1982, The Journal of pharmacology and experimental therapeutics.

[71]  L. Roncoroni,et al.  Cardiovascular Effects of AR‐L115 BS in Conscious Dogs With and Without Chronic Congestive Heart Failure , 1982, Journal of cardiovascular pharmacology.

[72]  C. P. Hsieh,et al.  Cardiovascular Properties of a New Cardiotonic Agent: MDL 17,043 (1,3‐Dihydro-4‐methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol‐2-one) , 1982, Journal of cardiovascular pharmacology.

[73]  E. Sonnenblick,et al.  Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease. , 1982, The American journal of medicine.

[74]  E. Sonnenblick,et al.  Acute Substantial Benefit of Inotropic Therapy with Amrinone on Exercise Hemodynamics and Metabolism in Severe Congestive Heart Failure , 1981, Circulation.

[75]  E. Braunwald,et al.  Problems in assessment of new pharmacologic agents for the heart failure patient. , 1981, American heart journal.

[76]  E. Sonnenblick,et al.  Beneficial effect of amrinone on myocardial oxygen consumption during acute left ventricular failure in dogs. , 1981, The American journal of cardiology.

[77]  E. Sonnenblick,et al.  Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. , 1981, The American journal of cardiology.

[78]  A. Fishman,et al.  Amrinone and exercise performance in patients with chronic heart failure. , 1981, The American journal of cardiology.

[79]  E. Sonnenblick,et al.  Relationship between amrinone plasma concentration and cardiac index , 1981, Clinical pharmacology and therapeutics.

[80]  J. Satriano,et al.  The effects of amrinone on transport and cyclic AMP metabolism in toad urinary bladder. , 1981, The Journal of pharmacology and experimental therapeutics.

[81]  H. Sebening,et al.  The comparison of the effects of AR-L 115 BS and dobutamine in patients with severe cardiac failure. , 1981, Arzneimittel-Forschung.

[82]  R. Huxtable,et al.  Differential effects of amrinone on contractility and taurine influx in rat and guinea pig hearts. , 1980, European journal of pharmacology.

[83]  J. Parker,et al.  Effects of amrinone, a cardiotonic drug, on calcium movements in dog erythrocytes. , 1980, The Journal of clinical investigation.

[84]  E. Braunwald,et al.  Effects of amrinone on experimental acute myocardial ischaemic injury. , 1980, Cardiovascular research.

[85]  E. Braunwald,et al.  Effects of Amrinone on Myocardial Energy Metabolism and Hemodynamics in Patients with Severe Congestive Heart Failure Due to Coronary Artery Disease , 1980, Circulation.

[86]  J. Cohn.  Progress in vasodilator therapy for heart failure. , 1980, The New England journal of medicine.

[87]  E. Braunwald,et al.  Oral amrinone in refractory congestive heart failure. , 1980, The American journal of cardiology.

[88]  I. Grupp,et al.  Direct vasodilator and positive inotropic actions of amrinone. , 1980, Journal of molecular and cellular cardiology.

[89]  E. Sonnenblick,et al.  Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure. , 1980, The American journal of cardiology.

[90]  G. Y. Lesher,et al.  Cardiotonic Activity of Amrinone–Win 40680 [5‐Amino‐3,4f‐bipyridin‐6(lH)‐one] , 1979, Circulation research.

[91]  A. Katz.  A new inotropic drug: its promise and a caution. , 1978, The New England journal of medicine.